Plain-English translation of NCT05736978 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a personalized approach to treating acute myeloid leukemia (AML) in patients who are not healthy enough for standard intensive chemotherapy. You would receive two base medications— and —and after two weeks, doctors would check your blood to see how well the treatment is working. If the early blood results show the leukemia cells are still present, a third medication called would be added to your treatment plan.
Many patients with AML cannot tolerate the strongest chemotherapy treatments because of their age or other health conditions. This trial is designed to find out whether tailoring treatment based on how patients respond in the first two weeks can improve outcomes and help more people achieve remission.
You likely qualify if…
You likely don't qualify if…
You would receive the two base medications in 28-day cycles: as injections on days 1–7, and as a tablet starting on day 1 and increasing over the first three days, then continuing through day 28. On day 14, you would have blood work to check how you are responding. Based on those results, your doctor may add a third medication on days 15 and 22. You would continue treatment in cycles unless your leukemia goes into remission (at which point you may be eligible for a stem cell transplant) or the side effects become too severe.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China